BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30

$7.61−0.07 (-0.91%)

Close on Nov 13, 2026Market cap $1.94BP/E –Yield –

BioCryst Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

BioCryst Pharmaceuticals's EV/EBITDA was 4.9× on Apr 30, 2026.

Period	Period end	Value	Change (pts)
2026	Apr 30, 2026	4.9×	−16.1
2025	Dec 31, 2025	21.0×	–

Parsed from the XBRL in BioCryst Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BCRX.

Revenue growth60.3% · median 58.2%

Gross margin97.9% · median 92.2%

Operating margin-30.1% · median -20.5%

Net margin-37.4% · median -3.5%

Advertisement
300 × 250

See a number that looks wrong?